A. Geldhof

Het onmogelijke genieten: literatuurstudie over de doodsdrift volgens Freud en Lacan (2008)

Geldhof, A

Het onmogelijke genieten: literatuurstudie over de doodsdrift volgens Freud en Lacan (2008)

Geldhof, A

Tapering infliximab dosages after temporary dose increase does not affect treatment survival in an established RA population (2008)

Vander Cruyssen, Bert, WESTHOVENS, R, DUREZ, P, VAN DEN BOSCH, FILIP, Mielants, Herman, DE CLERCK, L, ...

Four year follow-up of infliximab in rheumatoid arthritis patients refractory to multiple dmard treatment: Long-term clinical effect and prediction of attrition (2006)

Vander Cruyssen, Bert, WESTHOVENS, R, DUREZ, P, Van Den Bosch, Filip, Mielants, Herman, DE CLERCK, L, ...

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity (2006)

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, WESTHOVENS, R, DUREZ, P, Van Den Bosch, Filip, ...

Prediction of dose escalation for rheumatoid arthritis patients under infliximab treatment (2006)

Van Looy, Stijn, Vander Cruyssen, Bert, Meeus, Jeroen, Wyns, Bart, WESTHOVENS, R, DUREZ, P, ...

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study (2005)

Corluy, L, Veys, E M, De Clerck, L, Peretz, A, ...

OBJECTIVES: To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks. METHODS: Patients...

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment (2005)

Cruyssen, B, Van Looy, S, Wyns, B, Westhovens, R, Durez, P, Malaise, M, ...

This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3 mg/kg+...

Das28 correlates best with the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients (2005)

Vander Cruyssen, Bert, Van Looy, Stijn, WESTHOVENS, R, DUREZ, P, Van Den Bosch, Filip, VEYS, EM, ...

Comparison of embryo quality in high-yielding dairy cows, in dairy heifers and in beef cows (2005)

Leroy, Jo, Opsomer, Geert, De Vliegher, Sarne, Vanholder, Tom, GOOSSENS, L, GELDHOF, A, ...

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment (2005)

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, WESTHOVENS, R, DUREZ, P, MALAISE, M, ...

DAS28 is a robust measure of the physician's clinical judgment of response infliximab therapy (2005)

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, WESTHOVENS, R, DUREZ, P, ...

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study (2005)

Durez, P., Corluy, L., Veys, E. M., De Clerck, L., Peretz, A., ...

Objectives. To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks. Methods. Patients...

A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study (2005)

Durez, P., Corluy, L., Veys, E. M., Clerck, L. De, Peretz, A., ...

Objectives. To analyse the effect of a dose increase in patients with severe rheumatoid arthritis (RA) with insufficient clinical response to 3 mg/kg infliximab every 8 weeks. Methods. Patients...

Timing of DAS28 in infliximab therapy: reply (2005)

Durez, P., Corluy, L., Veys, E., De Clerck, L., Peretz, A., ...

Timing of DAS28 in infliximab therapy: reply (2005)

Durez, P., Corluy, L., Veys, E., De Clerck, L., Peretz, A., ...

Immunogenization of a murine T-cell lymphoma via transfection with interferon-gamma (1995)

Geldhof, A, Vanden Driessche, T, Sibille, C, De Baetselier, P

Tumor cell variants were derived from the BW5147 T-cell lymphoma that differ in major histocompatibility complex (MHC) class I antigen expression, tumorigenicity and metastatic potential. In general,...

Metastasis of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Dk antigens (1994)

Geldhof, A, Bakkus, M, Toussaint-Demylle, D, Brijs, L, Thielemans, K, ...

In vivo inoculation of a low metastatic BW 5147 derived T-cell lymphoma variant into syngeneic mice, had led to the generation of a highly metastatic variant. The shift towards a more metastatic...

Metastasis of mouse t-lymphoma-cells is controlled by the level of major histocompatibility complex class-i h-2d(k) antigens (1994)

Geldhof, A, Bakkus, M, Toussaintdemylle, D, Brijs, L, Thielemans, K, ...

In vivo inoculation of a low metastatic BW 5147 derived T-cell lymphoma variant into syngeneic mice, had led to the generation of a highly metastatic variant. The shift towards a more metastatic...

Vroegtijdige opsporing van cervixcarcinoom binnen de eerste lijn. Wetenschappelijk eindverslag. Koning Boudewijnstichting. Programma Integratie van de Gezondheidszorg (1991)

VUYLSTEEK, K, Derese, Anselme, GELDHOF, A

Early screening for cervical carcinoma within primary prevention (1991)

Derese, Anselme, GELDHOF, A, VUYLSTEEK, K

Prognosis of carbon disulfide intoxication, preliminary findings (1984)

VANHOORNE, M, GELDHOF, A, De Bleecker, Jan